246 related articles for article (PubMed ID: 23238158)
1. Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers.
Jain R; Poisson L; Narang J; Gutman D; Scarpace L; Hwang SN; Holder C; Wintermark M; Colen RR; Kirby J; Freymann J; Brat DJ; Jaffe C; Mikkelsen T
Radiology; 2013 Apr; 267(1):212-20. PubMed ID: 23238158
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric MR Imaging of Diffusion and Perfusion in Contrast-enhancing and Nonenhancing Components in Patients with Glioblastoma.
Boonzaier NR; Larkin TJ; Matys T; van der Hoorn A; Yan JL; Price SJ
Radiology; 2017 Jul; 284(1):180-190. PubMed ID: 28240563
[TBL] [Abstract][Full Text] [Related]
3. Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor.
Jain R; Poisson LM; Gutman D; Scarpace L; Hwang SN; Holder CA; Wintermark M; Rao A; Colen RR; Kirby J; Freymann J; Jaffe CC; Mikkelsen T; Flanders A
Radiology; 2014 Aug; 272(2):484-93. PubMed ID: 24646147
[TBL] [Abstract][Full Text] [Related]
4. Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study.
Sawlani RN; Raizer J; Horowitz SW; Shin W; Grimm SA; Chandler JP; Levy R; Getch C; Carroll TJ
Radiology; 2010 May; 255(2):622-8. PubMed ID: 20413772
[TBL] [Abstract][Full Text] [Related]
5. Prediction of survival in patients affected by glioblastoma: histogram analysis of perfusion MRI.
Romano A; Pasquini L; Di Napoli A; Tavanti F; Boellis A; Rossi Espagnet MC; Minniti G; Bozzao A
J Neurooncol; 2018 Sep; 139(2):455-460. PubMed ID: 29721752
[TBL] [Abstract][Full Text] [Related]
6. The preliminary radiogenomics association between MR perfusion imaging parameters and genomic biomarkers, and their predictive performance of overall survival in patients with glioblastoma.
Liu X; Mangla R; Tian W; Qiu X; Li D; Walter KA; Ekholm S; Johnson MD
J Neurooncol; 2017 Dec; 135(3):553-560. PubMed ID: 28889246
[TBL] [Abstract][Full Text] [Related]
7. Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival.
Gahramanov S; Muldoon LL; Varallyay CG; Li X; Kraemer DF; Fu R; Hamilton BE; Rooney WD; Neuwelt EA
Radiology; 2013 Mar; 266(3):842-52. PubMed ID: 23204544
[TBL] [Abstract][Full Text] [Related]
8. Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.
Ken S; Deviers A; Filleron T; Catalaa I; Lotterie JA; Khalifa J; Lubrano V; Berry I; Péran P; Celsis P; Moyal EC; Laprie A
J Neurooncol; 2015 Sep; 124(3):465-73. PubMed ID: 26189058
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification.
Gupta A; Young RJ; Shah AD; Schweitzer AD; Graber JJ; Shi W; Zhang Z; Huse J; Omuro AM
Clin Neuroradiol; 2015 Jun; 25(2):143-50. PubMed ID: 24474262
[TBL] [Abstract][Full Text] [Related]
10. Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms.
Provenzale JM; York G; Moya MG; Parks L; Choma M; Kealey S; Cole P; Serajuddin H
AJR Am J Roentgenol; 2006 Oct; 187(4):1036-42. PubMed ID: 16985154
[TBL] [Abstract][Full Text] [Related]
11. Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors.
Paulson ES; Schmainda KM
Radiology; 2008 Nov; 249(2):601-13. PubMed ID: 18780827
[TBL] [Abstract][Full Text] [Related]
12. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
[TBL] [Abstract][Full Text] [Related]
13. Cerebral blood volume measurements by perfusion-weighted MR imaging in gliomas: ready for prime time in predicting short-term outcome and recurrent disease?
Bisdas S; Kirkpatrick M; Giglio P; Welsh C; Spampinato MV; Rumboldt Z
AJNR Am J Neuroradiol; 2009 Apr; 30(4):681-8. PubMed ID: 19179427
[TBL] [Abstract][Full Text] [Related]
14. Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters.
Bag AK; Cezayirli PC; Davenport JJ; Gaddikeri S; Fathallah-Shaykh HM; Cantor A; Han XS; Nabors LB
J Neurooncol; 2014 Nov; 120(2):361-70. PubMed ID: 25098699
[TBL] [Abstract][Full Text] [Related]
15. Improved perfusion MR imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol.
Gahramanov S; Muldoon LL; Li X; Neuwelt EA
Radiology; 2011 Dec; 261(3):796-804. PubMed ID: 21940504
[TBL] [Abstract][Full Text] [Related]
16. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
Schmainda KM; Zhang Z; Prah M; Snyder BS; Gilbert MR; Sorensen AG; Barboriak DP; Boxerman JL
Neuro Oncol; 2015 Aug; 17(8):1148-56. PubMed ID: 25646027
[TBL] [Abstract][Full Text] [Related]
17. Combined analysis of MGMT methylation and dynamic-susceptibility-contrast MRI for the distinction between early and pseudo-progression in glioblastoma patients.
Bani-Sadr A; Berner LP; Barritault M; Chamard L; Bidet CM; Eker OF; Hermier M; Guyotat J; Jouanneau E; Meyronet D; Gouttard S; D'Hombres A; Iziquierdo C; Honnorat J; Berthezène Y; Ducray F
Rev Neurol (Paris); 2019 Oct; 175(9):534-543. PubMed ID: 31208813
[TBL] [Abstract][Full Text] [Related]
18. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.
Gahramanov S; Raslan AM; Muldoon LL; Hamilton BE; Rooney WD; Varallyay CG; Njus JM; Haluska M; Neuwelt EA
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):514-23. PubMed ID: 20395065
[TBL] [Abstract][Full Text] [Related]
19. MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set.
Gutman DA; Cooper LA; Hwang SN; Holder CA; Gao J; Aurora TD; Dunn WD; Scarpace L; Mikkelsen T; Jain R; Wintermark M; Jilwan M; Raghavan P; Huang E; Clifford RJ; Mongkolwat P; Kleper V; Freymann J; Kirby J; Zinn PO; Moreno CS; Jaffe C; Colen R; Rubin DL; Saltz J; Flanders A; Brat DJ
Radiology; 2013 May; 267(2):560-9. PubMed ID: 23392431
[TBL] [Abstract][Full Text] [Related]
20. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected].
Lev MH; Ozsunar Y; Henson JW; Rasheed AA; Barest GD; Harsh GR; Fitzek MM; Chiocca EA; Rabinov JD; Csavoy AN; Rosen BR; Hochberg FH; Schaefer PW; Gonzalez RG
AJNR Am J Neuroradiol; 2004 Feb; 25(2):214-21. PubMed ID: 14970020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
